Evaluation of V.A.C. VERAFLO CLEANSE CHOICE™ Dressing Using Normal Saline to Promote Increased Healthy Wound Bed Tissue

NCT ID: NCT04026334

Last Updated: 2022-08-01

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-07-25
• Study Completion Date: 2020-08-28

Brief Summary

The study goal is to evaluate the ability of the V.A.C. ULTA™ Negative Pressure Wound Therapy System and V.A.C. VERAFLO CLEANSE CHOICE ™ (VFCC) dressing system with saline as an irrigant in increasing viable tissue in full thickness wounds (such as chronic, acute, traumatic, sub-acute, and dehisced wounds and/or ulcers) with difficult to manage bioburden and slough.

Conditions

Wound; Wound Heal; Wounds and Injuries; Granulation Tissue; Negative-pressure Wound Therapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline

Group Type: EXPERIMENTAL

V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline

Intervention Type: DEVICE

-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy

Interventions

V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline

-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. is anticipated to be hospitalized for the duration of treatment.

2. is ≥22 years of age or their legally authorized representative is able to provide informed consent.

3. has a full thickness wound (such as chronic, acute, traumatic, sub-acute, and dehisced wounds and/or ulcers) measuring ≥4cm in length and ≥4cm in width (before removal of eschar at the bedside) excluding undermining/tunneling.

4. has, in the opinion of the investigator, no more than 2/3 of the visible wound bed surface area considered to be clean, healthy, and viable. If eschar is present at baseline, it must be removed by bedside debridement prior to assessing the percentage of clean, healthy, and viable wound bed.

5. has a negative urine or serum pregnancy test at screening (if female and has potential for pregnancy) and is willing to take precautionary measures to prevent pregnancy during the duration of the study (up to 9 days).

Exclusion Criteria

1. has been diagnosed with malignancy in the wound.

2. has untreated osteomyelitis.

3. has an untreated systemic infection.

4. has active cellulitis in the peri wound area.

5. has a known allergy or hypersensitivity to study materials: dressing and/or dressing components such as acrylic adhesives or polyurethane.

6. has, in the opinion of the investigator, a clinically significant condition that would impair the Subject's ability to comply with the study procedures.

7. has had radiation directly to the wound.

8. has been diagnosed with a major vascular deficit limiting arterial inflow to the wound region, as determined by the Investigator's interpretation of the Subject's medical history.

9. has eschar in the wound that cannot be removed by beside or sharp and/or mechanical debridement.

10. is participating in another interventional clinical trial for the duration of the study.

11. has unexplored fistulas in the wound or fistulas in the wound that connect to other body cavities.

12. has inadequate hemostasis at the wound site, as determined by the investigator.

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

3M

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Joseph M. Still Research Foundation

Augusta, Georgia, United States

Countries

United States

Other Identifiers

KCI.CLEANSE.CHOICE.2019.01

Identifier Type: -

Identifier Source: org_study_id